Hims & Hers' GLP-1 Pills Trigger Crackdown
Digital health company Hims & Hers Health is facing regulatory scrutiny over its compounded GLP-1 weight-loss pills. The move has reportedly accelerated a broader crackdown on custom drug compounding. The development serves as a cautionary example for digital health brands operating at the edge of wellness and pharmaceutical regulations.
- The controversy began after Hims & Hers announced plans for a compounded oral semaglutide pill for as little as $49 per month, a significantly lower-cost alternative to the newly released Wegovy pill from Novo Nordisk, priced at $149 per month. This move was seen as an attempt to capture a new market of patients who prefer oral medications over injections. - Novo Nordisk, the manufacturer of Wegovy and Ozempic, responded by filing a patent infringement lawsuit against Hims & Hers, accusing the company of unlawfully mass-marketing unapproved versions of its FDA-approved semaglutide medicines. Novo Nordisk alleged that Hims' products could contain dangerous impurities or incorrect dosages. - The FDA allows for the creation of compounded drugs when an FDA-approved drug is in short supply. GLP-1 drugs were on the FDA's shortage list for much of 2023 and 2024, which allowed companies like Hims & Hers to offer compounded versions. However, the FDA declared the shortages resolved in late 2024 and early 2025, removing the primary legal basis for routine compounding. - In response to Hims & Hers' announcement, the FDA stated its intent to restrict access to the active pharmaceutical ingredients (APIs) used in unapproved, mass-marketed compounded GLP-1 drugs. The agency warned it would use all available enforcement tools, including seizure and injunction, against companies making unsubstantiated claims. - Following the regulatory and legal pressure, Hims & Hers quickly withdrew its plans to offer the compounded oral GLP-1 pill, just two days after its initial announcement. The Department of Health and Human Services also referred Hims & Hers to the Department of Justice for potential violations of the Federal Food, Drug, and Cosmetic Act. - The FDA has received hundreds of adverse event reports related to compounded semaglutide, including some requiring hospitalization due to dosing errors. The agency has also warned about fraudulent products with false labels and issues with maintaining the required refrigeration for injectable GLP-1 drugs during shipping. - Compounded drugs are not FDA-approved, meaning they do not undergo the same rigorous review for safety, effectiveness, and quality as commercially available medications. The FDA has found that some compounded versions contain different active ingredients, such as semaglutide salts, which have not been proven safe or effective.
